Abbott Laboratories plans to sell more than $10 billion of fixed-income securities this week, according to Fox News, as it prepares to spin off its pharmaceutical operations into a new company, AbbVie.
Abbott announced Friday that it was offering to buy back up to $7.7 billion in nine outstanding debt issues that mature between 2014 and 2040. It said that its subsidiary, AbbVie, will sell debt and use the proceeds to pay Abbott a dividend.
See the full story here.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
- Informative weekly newsletter featuring news, analysis, real-world case studies, and other critical content
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
